Joseph Ashil, Balakrishnan Abhilash, Shanmughan Prasanth, Maliakel Balu, Illathu Madhavamenon Krishnakumar
R&D Centre, Akay Natural Ingredients, Ambunadu, Malaidamthuruth P.O., Cochin 683561, India.
ACS Omega. 2022 Apr 6;7(15):12835-12845. doi: 10.1021/acsomega.2c00116. eCollection 2022 Apr 19.
The poor oral bioavailability, rapid biotransformation to less active metabolites, and fast elimination from systemic circulation have been identified as the major limitations responsible for the clinical insignificance of many drug candidates and phytonutrients. Despite the technological advancements in the nanoformulations of synthetic drugs, there exist many challenges for nutritional therapy, due to the regulatory issues, use of high levels of synthetic emulsifiers and polymers, low stability, low loading levels, mainly liquid state, etc. Herein, we report the characterization and human pharmacokinetics of a natural self-emulsifying hybrid-hydrogel formulation of -resveratrol prepared by uniformly impregnating resveratrol micelles into the fenugreek galactomannan hydrogel scaffold to form a water-soluble micelle/hydrogel composite in powder form (RF-20). Fourier transform infrared spectroscopy (FTIR), powder X-ray diffraction (PXRD), scanning electron microscopy (SEM), particle size analysis by dynamic light scattering (DLS), and transmission electron microscopy (TEM) demonstrated the uniform impregnation of resveratrol micelles within the galactomannan hydrogel matrix to form a soluble (average particle size of 172.0 ± 10.4 nm and -21.0 ± 2.5 mV zeta potential) and amorphous powder form with smooth and translucent surface morphology for RF-20, with no chemical alterations. Upon pharmacokinetic studies on healthy human subjects ( = 16) following a randomized, double-blinded, placebo-controlled, 2-arm, 4-sequence crossover design and tandem mass spectrometry (UPLC-ESI-MS/MS), 80 mg of -resveratrol from RF-20 provided enhanced free resveratrol bioavailability and pharmacokinetic properties compared to the unformulated resveratrol with 98% purity. The enhancement in bioavailability was more when supplemented in sachet (12.98-fold) form than the capsule (10.48-fold) with improved absorption ( = 50.97 ± 15.82 ng/mL), circulation half-life ( = 7.01 ± 1.44 h), and sustained delivery ( = 4.71 ± 0.73 h), as compared to the unformulated form ( = 15.07 ± 5.10 ng/mL; = 1.58 ± 0.65 h; = 1.21 ± 0.42 h).
口服生物利用度差、迅速生物转化为活性较低的代谢产物以及从体循环中快速消除,已被确定为导致许多候选药物和植物营养素临床意义不大的主要限制因素。尽管合成药物的纳米制剂在技术上取得了进步,但由于监管问题、高含量合成乳化剂和聚合物的使用、稳定性低、载药量低、主要为液态等原因,营养疗法仍面临许多挑战。在此,我们报告了一种天然自乳化混合水凝胶制剂——白藜芦醇的表征和人体药代动力学,该制剂是通过将白藜芦醇胶束均匀浸渍到胡芦巴半乳甘露聚糖水凝胶支架中,形成粉末状的水溶性胶束/水凝胶复合物(RF-20)。傅里叶变换红外光谱(FTIR)、粉末X射线衍射(PXRD)、扫描电子显微镜(SEM)、动态光散射粒度分析(DLS)和透射电子显微镜(TEM)表明,白藜芦醇胶束均匀浸渍在半乳甘露聚糖水凝胶基质中,形成了一种可溶性(平均粒径为172.0±10.4 nm,ζ电位为-21.0±2.5 mV)且表面形态光滑半透明的无定形粉末状RF-20,且无化学变化。在对健康人类受试者(n = 16)进行药代动力学研究时,采用随机、双盲、安慰剂对照、双组、四序列交叉设计和串联质谱法(UPLC-ESI-MS/MS),与纯度为98%的未制剂化白藜芦醇相比,来自RF-20的80 mg白藜芦醇提供了更高的游离白藜芦醇生物利用度和药代动力学特性。以小袋(12.98倍)形式补充时的生物利用度提高幅度大于胶囊(10.48倍),吸收(Cmax = 50.97±15.82 ng/mL)、循环半衰期(t1/2 = 7.01±1.44 h)和持续释放(MRT = 4.71±0.73 h)均有所改善,相比之下,未制剂化形式为(Cmax = 15.07±5.10 ng/mL;t1/2 = 1.58±0.65 h;MRT = 1.21±0.42 h)。